Health Care Biotech and Pharmaceuticals

More

  • Alnylam CEO: Whole new way to treat disease Friday, 11 Dec 2015 | 6:38 AM ET
    Alnylam CEO: Whole new way to treat disease

    John Maraganore, Alnylam Pharmaceuticals president & CEO, and CNBC's Meg Tirrell, discuss the company's research into RNAi therapy, a process which turns off the gene's ability to "do something bad." Also Maraganore weighs in on drug pricing.

  • Taking ownership of your health Thursday, 10 Dec 2015 | 1:24 PM ET
    Taking ownership of your health

    CNBC's Meg Tirrell provides insight to her experience getting her genome sequenced, and which companies are competing in the DNA mapping industry.

  • Major players in DNA mapping Thursday, 10 Dec 2015 | 11:24 AM ET
    Major players in DNA mapping

    CNBC's Meg Tirrell takes a look at the future of personalized medicine, and which businesses are competing in the genome space.

  • Alexion CEO: We are thrilled with FDA approval Thursday, 10 Dec 2015 | 8:18 AM ET
    Alexion CEO: We are thrilled with FDA approval

    CNBC's Meg Tirrell and David Hallal, Alexion Pharmaceuticals CEO, discuss the FDA's approval of the company's enzyme replacement drug Kanuma and weighs in on drug pricing.

  • A glimpse into the future of genome sequencing Thursday, 10 Dec 2015 | 6:54 AM ET
    A glimpse into the future of genome sequencing

    CNBC's Meg Tirrell takes a look at advances in the Human Genome Project and the future of personalize medicine.

  • How $199 unlocks a wealth of health data Thursday, 10 Dec 2015 | 6:50 AM ET
    23andMe spit kit packaged for the mass market for genome sequencing.

    A $199 service from health company 23andMe gives individuals data from ancestry to risks of carrying a genetic condition.

  • Genome sequencing: A glimpse of the future Thursday, 10 Dec 2015 | 6:50 AM ET
    Genome sequencing: A glimpse of the future

    Imagine a test that could give you a glimpse of your future… CNBC reporter Meg Tirrell underwent whole genome sequencing to map her DNA and discovered as many questions as answers.

  • Unlocking my genome: Was it worth it? Thursday, 10 Dec 2015 | 6:50 AM ET
    DNA human genome

    Before testing your own genome, it helps to realize it can raise more questions than it answers.

  • Second half trades as markets sell off Wednesday, 9 Dec 2015 | 1:44 PM ET

    The "Halftime Report" panelists discuss their strategies as the final three hours of the trading day begins.

  • Big pharma should stop throwing a hissy fit Wednesday, 9 Dec 2015 | 10:41 AM ET
    Cold and allergy medicine display in a drug store.

    Big pharma is angry over the TPP but the pact actually does more to promote drug innovation than any trade agreement in history, says this professor.

  • Valeant considers selling contact lens maker Tuesday, 8 Dec 2015 | 8:59 AM ET
    The headquarters of Valeant Pharmaceuticals International in Laval, Quebec.

    Valeant is reaching out to potential buyers for its specialty contact lens manufacturing division, according to two people familiar with the matter.

  • Sickle cell skepticism Monday, 7 Dec 2015 | 2:15 PM ET
    Sickle cell skepticism

    CNBC's Meg Tirrell talks to the CEO of Global Blood Therapeutics, which has been hit today after disappointing data from its new sickle cell treatment. CEO Ted Love explains what's next for the company.

  • A new cancer treatment? Monday, 7 Dec 2015 | 11:40 AM ET
    A new cancer treatment?

    CNBC's Meg Tirrell details the potential of Car-T immunotherapy as a new cancer treatment.

  • Tackling cancer differently Monday, 7 Dec 2015 | 8:32 AM ET
    Lab science research

    Agios CEO David Schenkein, presents data from nearly 300 patients with serious acute myeloid leukemia.

  • Treating sickle cell disease Monday, 7 Dec 2015 | 6:51 AM ET
    Treating sickle cell disease

    Gauging progress in early data for treating sickle cell, a disease which causes sickle-shaped red blood cells, with Bluebird Bio CEO Nick Leschly.

  • Woman feels physical pain for first time at age 39 Friday, 4 Dec 2015 | 2:44 PM ET

    A drug meant to treat opioid overdoses gave a woman the chance to feel a sensation completely new to her: pain.

  • Your first trade for Friday Thursday, 3 Dec 2015 | 6:18 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Health-care CEOs: This is holding back the US Thursday, 3 Dec 2015 | 4:06 PM ET
    Ken Frazier, president and CEO of Merck.

    The U.S. is at a disadvantage because of this, two health-care CEOs said.

  • Top strategist: Get ready for ‘difficult’ year Thursday, 3 Dec 2015 | 9:38 AM ET
    Doug Ramsey, chief investment officer at The Leuthold Group.

    Doug Ramsey, chief investment officer at The Leuthold Group, answers investment questions from CNBC Pro subscribers.

  • Turing hit again by competition Tuesday, 1 Dec 2015 | 2:57 PM ET
    Turing hit again by competition

    Express Scripts announced today that it will partner with Imprimis Pharmaceuticals to provide a $1 alternative to Turing Pharmaceuticals' Daraprim. CNBC's Meg Tirrell reports.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.